Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+breast cancer.

被引：1
|
作者：
Esfahani, Khashayar
Ferrario, Cristiano
Le, Philippe
Panasci, Lawrence C.
机构：
[1] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Montreal, PQ, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e11585
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11585
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Adjuvant trastuzumab and vinorelbine (TV) for early-stage HER2+breast cancer.
    McLaughlin, Shannon
    Nakajima, Erika
    Isakoff, Steven J.
    Shin, Jennifer
    Moy, Beverly
    Bardia, Aditya
    Kuter, Irene
    Spring, Laura
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Adjuvant trastuzumab and vinorelbine for early-stage HER2+breast cancer
    McLaughlin, Shannon
    Nakajima, Erika
    Bar, Yael
    Hutchinson, Jennifer A. A.
    Shin, Jennifer
    Moy, Beverly
    Isakoff, Steven J. J.
    Bardia, Aditya
    Kuter, Irene
    Spring, Laura M. M.
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [3] Safety of trastuzumab in women with HER2+breast cancer.
    Nowsheen, Somaira
    Aziz, Khaled
    Park, Jae Yoon
    Villarraga, Hector R.
    Herrmann, Joerg
    Ruddy, Kathryn Jean
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer.
    Bayo, J
    Mayordomo, JI
    Sanchez-Rovira, P
    Perez-Carrion, R
    Illaramendi, J
    Flores, EG
    Bueno, JMG
    Vazquez, MR
    Crespo, C
    Palomo, AG
    Huelva, HJRJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
  • [5] Factors associated with non use of adjuvant trastuzumab in older patients with HER2+breast cancer.
    Luis, Ines Vaz
    Lin, Nancy U.
    Keating, Nancy Lynn
    Barry, William Thomas
    Lii, Joyce
    Burstein, Harold J.
    Winer, Eric P.
    Freedman, Rachel A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+breast cancer.
    Garrison, L. P., Jr.
    Perez, E. A.
    Dueck, A.
    Lalla, D.
    Paton, V.
    Lubeck, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 306S - 306S
  • [7] Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancer
    Ferretti, Gianluigi
    Papaldo, Paola
    Fabi, Alessandra
    Carlini, Paolo
    Felici, Alessandra
    Cognetti, Francesco
    [J]. ONCOLOGIST, 2006, 11 (07): : 853 - 854
  • [8] STAT6 expression and trastuzumab resistance in HER2+breast cancer.
    Cobleigh, Melody A.
    DiScala, Molly
    Najor, Matthew S.
    Yung, Timothy
    Abukhdeir, Abde M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+breast cancer
    Lammers, Philip E.
    Dank, Magdolna
    Masetti, Riccardo
    Abbas, Richat
    Hilton, Fiona
    Coppola, Jennifer
    Jacobs, Ira
    [J]. BRITISH JOURNAL OF CANCER, 2018, 119 (03) : 266 - 273
  • [10] Trastuzumab (T) plus vinorelbine (VNR) as first combination in Her-2 overexpressing patients with metastatic breast cancer.
    Glogowska, I
    Sienkiewicz-Kozlowska, R
    Bauer-Kosinska, B
    Jaczewska, S
    Pienkowski, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 235S - 235S
12345